BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design

被引：3

作者：

Tartof, Sara Y. ^{[1
,2
]}

Frankland, Timothy B. ^{[3
]}

Puzniak, Laura ^{[4
]}

Slezak, Jeff M. ^{[1
]}

Hong, Vennis ^{[1
]}

Takhar, Harpreet ^{[1
]}

Ogun, Oluwaseye A. ^{[1
]}

Simmons, Sarah ^{[1
]}

Xie, Fagen ^{[1
]}

Zamparo, Joann ^{[4
]}

Ackerson, Bradley K. ^{[5
]}

Jodar, Luis ^{[4
]}

McLaughlin, John M. ^{[4
]}

机构：

[1] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 1000 S Los Robles,2nd Floor, Pasadena, CA 91101 USA

[2] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA

[3] Kaiser Permanente Hawaii Ctr Integrated Hlth Care, Honolulu, HI USA

[4] Pfizer Inc, Collegeville, PA USA

[5] Southern Calif Permanente Med Grp, Harbor City, CA USA

来源：

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY | 2023年 / 12卷 / 03期

关键词：

BNT162b2; booster; COVID-19; delta; effectiveness; Kaiser Permanente; omicron; pediatric; real-world; SARS-CoV-2; test-negative; United States; VACCINE;

D O I：

10.1093/jpids/piad005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after >= 3 months. A booster improved protection to 77% [53-88].

引用

页码：177 / 179

页数：3

共 50 条

[41] Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years
Toepfner, Nicole
von Meissner, Wolfgang C. G.
Strumann, Christoph
Drinka, Denisa
Stuppe, David
Jorczyk, Maximilian
Moor, Jeanne
Puschel, Johannes
Liss, Melanie
von Poblotzki, Emilie
Berner, Reinhard
Moor, Matthias B.
Chao, Cho-Ming
JAMA NETWORK OPEN, 2022, 5 (10) : E2237140
[42] Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
Chung, Hannah
He, Siyi
Nasreen, Sharifa
Sundaram, Maria E.
Buchan, Sarah A.
Wilson, Sarah E.
Chen, Branson
Calzavara, Andrew
Fell, Deshayne B.
Austin, Peter C.
Wilson, Kumanan
Schwartz, Kevin L.
Brown, Kevin A.
Gubbay, Jonathan B.
Basta, Nicole E.
Mahmud, Salaheddin M.
Righolt, Christiaan H.
Svenson, Lawrence W.
MacDonald, Shannon E.
Janjua, Naveed Z.
Tadrous, Mina
Kwong, Jeffrey C.
BMJ-BRITISH MEDICAL JOURNAL, 2021, 374
[43] Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study
Moor, Jeanne
Toepfner, Nicole
von Meissner, Wolfgang C. G.
Berner, Reinhard
Moor, Matthias B.
Kublickiene, Karolina
Strumann, Christoph
Chao, Cho-Ming
BIOLOGY OF SEX DIFFERENCES, 2024, 15 (01)
[44] Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
Elio Novembre
Mariangela Tosca
Carlo Caffarelli
Mauro Calvani
Fabio Cardinale
Riccardo Castagnoli
Elena Chiappini
Claudio Cravidi
Michele Miraglia Del Giudice
Marzia Duse
Amelia Licari
Sara Manti
Alberto Martelli
Giampaolo Ricci
Giuseppe Pingitore
Gian Luigi Marseglia
Italian Journal of Pediatrics, 48
[45] The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age
Cinicola, Bianca Laura
Mortari, E. Piano
Zicari, Anna Maria
Agrati, Chiara
Bordoni, Veronica
Albano, Christian
Fedele, Giorgio
Schiavoni, Ilaria
Leone, Pasqualina
Fiore, Stefano
Capponi, Martina
Conti, Maria Giulia
Petrarca, Laura
Stefanelli, Paola
Spalice, Alberto
Midulla, Fabio
Palamara, Anna Teresa
Quinti, Isabella
Locatelli, Franco
Carsetti, Rita
FRONTIERS IN IMMUNOLOGY, 2022, 13
[46] COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS)
Ludwikowska, Kamila M.
Popiel, Aneta
Matkowska-Kocjan, Agnieszka
Biela, Mateusz
Wojcik, Marta
Szenborn, Filip
Wielgos, Katarzyna
Pielka-Markiewicz, Ewa
Zaryczanski, Janusz
Kursa, Miron B.
Szenborn, Leszek
VACCINE, 2023, 41 (21) : 3317 - 3327
[47] Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study
Tartof, Sara Y.
Slezak, Jeff M.
Puzniak, Laura
Hong, Vennis
Xie, Fagen
Ackerson, Bradley K.
Valluri, Srinivas R.
Jodar, Luis
McLaughlin, John M.
LANCET RESPIRATORY MEDICINE, 2022, 10 (07): : 689 - 699
[48] BNT162b2 mRNA Vaccination Against COVID-19 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021-April 2022
Zambrano, Laura D.
Newhams, Margaret M.
Olson, Samantha M.
Halasa, Natasha B.
Price, Ashley M.
Orzel, Amber O.
Young, Cameron C.
Boom, Julie A.
Sahni, Leila C.
Maddux, Aline B.
Bline, Katherine E.
Kamidani, Satoshi
Tarquinio, Keiko M.
Chiotos, Kathleen
Schuster, Jennifer E.
Cullimore, Melissa L.
Heidemann, Sabrina M.
Hobbs, Charlotte, V
Nofziger, Ryan A.
Pannaraj, Pia S.
Cameron, Melissa A.
Walker, Tracie C.
Schwartz, Stephanie P.
Michelson, Kelly N.
Coates, Bria M.
Flori, Heidi R.
Mack, Elizabeth H.
Smallcomb, Laura
Gertz, Shira J.
Bhumbra, Samina S.
Bradford, Tamara T.
Levy, Emily R.
Kong, Michele
Irby, Katherine
Cvijanovich, Natalie Z.
Zinter, Matt S.
Bowens, Cindy
Crandall, Hillary
Hume, Janet R.
Patel, Manish M.
Campbell, Angela P.
Randolph, Adrienne G.
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E90 - E100
[49] Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
Florentino, Pilar T., V
Millington, Tristan
Cerqueira-Silva, Thiago
Robertson, Chris
Oliveira, Vinicius de Araujo
Junior, Juracy B. S.
Alves, Flavia J. O.
Penna, Gerson O.
Katikireddi, Srinivasa Vital
Boaventura, Viviane S.
Werneck, Guilherme L.
Pearce, Neil
McCowan, Colin
Sullivan, Christopher
Agrawal, Utkarsh
Grange, Zoe
Ritchie, Lewis D.
Simpson, Colin R.
Sheikh, Aziz
Barreto, Mauricio L.
Rudan, Igor
Barral-Netto, Manoel
Paixao, Enny S.
LANCET INFECTIOUS DISEASES, 2022, 22 (11): : 1577 - 1586
[50] Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study
Tartof, Sara Y.
Slezak, Jeff M.
Puzniak, Laura
Hong, Vennis
Frankland, Timothy B.
Ackerson, Bradley K.
Xie, Fagen
Takhar, Harpreet
Ogun, Oluwaseye A.
Simmons, Sarah
Zamparo, Joann M.
Valluri, Srinivas R.
Jodar, Luis
Mclaughlin, John M.
LANCET RESPIRATORY MEDICINE, 2023, 11 (12): : 1089 - 1100

← 1 2 3 4 5 →